Manmeet Soni Biography and Net Worth



Manmeet S. Soni CPA serves as Chief Financial Officer, Chief Operating Officer, Executive Vice President of the Company. He served as Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. from May 2017 until August 2019. From March 2016 to February 2017, Mr. Soni served as the Executive Vice President, Chief Financial Officer, and Treasurer of ARIAD Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, when ARIAD was acquired by Takeda Pharmaceutical Company Limited. Mr. Soni continued as an employee of ARIAD through May 2017. Previously, Mr. Soni served as Chief Financial Officer and Treasurer of Pharmacyclics, Inc., a publicly-held biopharmaceutical company, until its acquisition by AbbVie, Inc. in May 2015, after which he supported AbbVie during the post-acquisition transition through September 2015. He first joined Pharmacyclics in September 2012 as Corporate Controller and was promoted to serve as Principal Accounting and Financial Officer, Treasurer in August 2013, prior to being appointed as Chief Financial Officer and Treasurer in February 2014. Prior to joining Pharmacyclics, Mr. Soni worked at ZELTIQ Aesthetics Inc., a publicly-held medical technology company as Corporate Controller. Prior to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers from June 2007 to January 2012 in their Life Science and Venture Capital Group. Prior to that, he worked at PricewaterhouseCoopers India, providing audit and assurance services. Mr. Soni serves as a member of the board of directors of Pulse Biosciences, Inc. and Arena Pharmaceuticals, Inc. Mr. Soni graduated from Hansraj College at Delhi University in India. He is a certified public accountant and completed his Chartered Accountancy from the Institute of Chartered Accountants of India.

What is Manmeet Singh Soni's net worth?

The estimated net worth of Manmeet Singh Soni is at least $297.59 million as of October 13th, 2023. Mr. Soni owns 2,976,190 shares of Arena Pharmaceuticals stock worth more than $297,589,238 as of March 29th. This net worth approximation does not reflect any other investments that Mr. Soni may own. Learn More about Manmeet Singh Soni's net worth.

How do I contact Manmeet Singh Soni?

The corporate mailing address for Mr. Soni and other Arena Pharmaceuticals executives is 6154 Nancy Ridge Drive, San Diego CA, 92121. Arena Pharmaceuticals can also be reached via phone at (858) 453-7200 and via email at [email protected]. Learn More on Manmeet Singh Soni's contact information.

Has Manmeet Singh Soni been buying or selling shares of Arena Pharmaceuticals?

Manmeet Singh Soni has not been actively trading shares of Arena Pharmaceuticals during the last quarter. Most recently, Manmeet Singh Soni sold 304 shares of the business's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $62.74, for a transaction totalling $19,072.96. Following the completion of the sale, the director now directly owns 5,902 shares of the company's stock, valued at $370,291.48. Learn More on Manmeet Singh Soni's trading history.

Who are Arena Pharmaceuticals' active insiders?

Arena Pharmaceuticals' insider roster includes Vincent Aurentz (VP), Christopher Cabell (CMO), Jayson Dallas (Director), Robert Lisicki (EVP), Amit Munshi (CEO), Tina Nova (Director), and Manmeet Soni (Director). Learn More on Arena Pharmaceuticals' active insiders.

Manmeet Singh Soni Insider Trading History at Arena Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2020Sell304$62.74$19,072.965,902View SEC Filing Icon  
6/15/2020Sell1,327$60.12$79,779.247,533View SEC Filing Icon  
See Full Table

Manmeet Singh Soni Buying and Selling Activity at Arena Pharmaceuticals

This chart shows Manmeet Singh Soni's buying and selling at Arena Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arena Pharmaceuticals Company Overview

Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $99.99
Low: $99.99
High: $99.99

50 Day Range

MA: $97.65
Low: $93.13
High: $99.99

2 Week Range

Now: $99.99
Low: $45.50
High: $100.00

Volume

107 shs

Average Volume

1,561,326 shs

Market Capitalization

$6.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55